| Name | Title | Contact Details |
|---|
Vener8 is a technology holding company that commercializes proven technologies from leading corporate partners. By focusing on the intersection of platform technologies in large markets facing technical challenges, with entrepreneurial teams of vision, execution, and sales capability, Vener8 is building businesses that matter.
Britannia, Inc. is a Westwood, KS-based company in the Software and Internet sector.
VMware is the leader in cloud infrastructure, business mobility and virtualization software. A pioneer in the use of virtualization and policy-driven automation technologies, VMware simplifies IT complexity across the entire data center to the virtual workplace, empowering customers with solutions in the software-defined data center to hybrid cloud computing and the mobile workspace. With 2014 revenues of $6.04 billion, VMware has more than 500,000 customers, 75,000 partners, and 18,000+ employees in 120+ locations around the world. At the core of what we do are our employees who deeply value execution, passion, integrity, customers, and community.
The Omega Group is a San Diego, CA-based company in the Software and Internet sector.
Cypher Genomics is a leading genome informatics company offering a highly accurate, rapid and robust interpretation software solution for users of human genome sequencing. The proprietary, automated genomic interpretation platform allows clinical laboratories to tune Cypher Genomics' market leading sensitivity and specificity profiles to develop molecular tests for diagnostic and prognostic use, and pharmaceutical companies to discover biomarkers from whole genome sequence data in sample sizes typical of early stage drug development studies. Through Mantis™, the genome interpretation software as a service offering, and Coral™, a biomarker discovery service, Cypher Genomics can improve health care and reduce costs by facilitating improved diagnostic accuracy and earlier interventions, optimizing therapeutic approaches and reducing adverse drug reactions. The gap between the ability to generate whole genome sequences at scale and the primarily manual process of interpretation to date creates a significant unmet need that is well served by the Cypher Genomics solution.